High-dose methotrexate: Insecure rationale: Take 2

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 9, 2008, Pages 639-640

  Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; HUMAN; MEDICAL LITERATURE; NOTE; OSTEOSARCOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE;

EID: 66249094536     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318185f4ee     Document Type: Note

References (13)

1. Djerassi I. High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3490) rescue: background and rationale. Cancer Chemother Rep (Part 3). 1975;6:3-6.
2. Kamen BA, Winick NJ. High dose methotrexate therapy: insecure rationale? Biochem Pharmacol. 1988;37:2713-2715.
3. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5:2017-2031.
4. Djerassi I, Farber S, Abir E, et al. Continuous infusion of methotrexate in children with acute leukemia. Cancer. 1967;20: 233-322.
5. Blay JY. Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle. Onkologie. 2007;30: 226-227.
6. Sorich MJ, Pottier N, Pei D, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. P LoS Med. 2008;5:e83.
7. Vezmar S, Becker A, Bode U, et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;4:92-104.
8. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol. 1993;11:5-14.
9. Pui CH, Relling MV, Evans WE. Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia? Leuk Lymphoma. 2006;47:2431-2432.
10. Samuels L, Feinberg A, Moccio D, et al. Detection by high-performance liquid chromatography of methotrexate and its metabolites in tumor tissue from osteosarcoma patients treated with high-dose methotrexate/leucovorin rescue. Biochem Pharmacol. 1984;33:2711-2714.
11. Winick NJ, Kamen BA, Streckfuss A, et al. Methotrexate (MTX) concentration in tumors following low dose MTX. Cancer Chemother Pharmacol. 1987;20:78-80.
12. Kamen B. Folate and antifolate pharmacology. Semin Oncol. 1997; 24(suppl 18):30-39.
13. Hum MC, Smith AK, Lark RH, et al. Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro. Pharmacotherapy. 1997;17:1260-1266.